DK2809681T3 - ANTI-ASIC1-antistoffer og anvendelser deraf - Google Patents

ANTI-ASIC1-antistoffer og anvendelser deraf Download PDF

Info

Publication number
DK2809681T3
DK2809681T3 DK13702876.7T DK13702876T DK2809681T3 DK 2809681 T3 DK2809681 T3 DK 2809681T3 DK 13702876 T DK13702876 T DK 13702876T DK 2809681 T3 DK2809681 T3 DK 2809681T3
Authority
DK
Denmark
Prior art keywords
ser
gly
thr
tyr
leu
Prior art date
Application number
DK13702876.7T
Other languages
English (en)
Inventor
Lynn Macdonald
Min Gao
Marc R Morra
Michael L Lacroix-Fralish
Nicole M Alessandri-Haber
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47666522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2809681(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK2809681T3 publication Critical patent/DK2809681T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (7)

1. Isoleret antistof eller antigen-bindingsfragment deraf, der specifikt binder celleoverflade-udtrykt ASIC1 (SEQ ID NO: 401), hvor antistoffet eller antigenbindingsfragmentet omfatter et tungkæde-komplementaritetsbestemmende område (HCDR) 1 med aminosyresekvensen ifølge SEQ ID NO: 36, et HCDR2 med aminosyresekvensen ifølge SEQ ID NO: 38, et HCDR3 med aminosyresekvensen ifølge SEQ ID NO: 40, et letkæde-komplementaritetsbestemmende område (LCDR) 1 med aminosyresekvensen ifølge SEQ ID NO: 44, et LCDR2 med aminosyresekvensen ifølge SEQ ID NO: 46 og et LCDR3 med aminosyresekvensen ifølge SEQ ID NO: 48.
2. Isoleret antistof eller antigen-bindingsfragment ifølge krav 1, hvor antistoffet eller antigen-bindingsfragmentet omfatter et variabelt tungkædeområde (HCVR) med aminosyresekvensen ifølge SEQ ID NO: 34 og et variabelt letkædeområde (LCVR) med aminosyresekvensen ifølge SEQ ID NO: 42.
3. Isoleret antistof eller antigen-bindingsfragment deraf, der konkurrerer om binding til celleoverflade-udtrykt ASIC1 med et referenceantistof, der omfatter et HCVR med aminosyresekvensen ifølge SEQ ID NO: 34 og et LCVR med aminosyresekvensen ifølge SEQ ID NO: 42.
4. Isoleret antistof, eller antigen-bindingsfragment deraf, der specifikt binder celleoverflade-udtrykt ASIC1 (SEQ ID NO: 401), hvor antistoffet eller antigenbindingsfragmentet omfatter tung- og letkæde-CDR’er af et HCVR/LCVR-aminosyresekvenspar med aminosyresekvensen ifølge SEQ ID NO: 34 og 42.
5. Farmaceutisk sammensætning, der omfatter antistoffet eller antigenbindingsfragmentet ifølge et hvilket som helst af kravene 1 til 4 og en farmaceutisk acceptabel bærer eller fortynder.
6. Isoleret antistof eller antigen-bindingsfragment ifølge et hvilket som helst af kravene 1 til 4, eller den farmaceutiske sammensætning ifølge krav 5, til anvendelse i en fremgangsmåde til behandling eller lindring af smerte.
7. Isoleret antistof eller antigen-bindingsfragment eller farmaceutisk sammensætning til anvendelse ifølge krav 6, hvor smerten er (a) cancer-associeret smerte eller kemoterapi-induceret smerte eller (b) nociceptiv smerte eller visceral smerte, eventuelt forbundet med en tilstand valgt fra gruppen bestående af inflammation, postoperativ incision, neuropati, knoglefraktur, forbrænding, osteoporotisk fraktur, knoglecancer, gigt, migrænehovedpine og fibromyalgi.
DK13702876.7T 2012-01-31 2013-01-30 ANTI-ASIC1-antistoffer og anvendelser deraf DK2809681T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261592837P 2012-01-31 2012-01-31
US201261644038P 2012-05-08 2012-05-08
US201261692925P 2012-08-24 2012-08-24
PCT/US2013/023784 WO2013116296A1 (en) 2012-01-31 2013-01-30 Anti-asic1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
DK2809681T3 true DK2809681T3 (da) 2019-03-11

Family

ID=47666522

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13702876.7T DK2809681T3 (da) 2012-01-31 2013-01-30 ANTI-ASIC1-antistoffer og anvendelser deraf
DK18201823.4T DK3453723T3 (da) 2012-01-31 2013-01-30 Anti-ASIC1-antistoffer og anvendelser deraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK18201823.4T DK3453723T3 (da) 2012-01-31 2013-01-30 Anti-ASIC1-antistoffer og anvendelser deraf

Country Status (33)

Country Link
US (3) US9150648B2 (da)
EP (2) EP2809681B1 (da)
JP (1) JP6302844B2 (da)
KR (1) KR102111941B1 (da)
CN (1) CN104093738B (da)
AR (1) AR089852A1 (da)
AU (1) AU2013215254B2 (da)
CA (1) CA2862332C (da)
CL (1) CL2014002019A1 (da)
CO (1) CO7020877A2 (da)
CY (2) CY1121368T1 (da)
DK (2) DK2809681T3 (da)
EA (1) EA028647B1 (da)
ES (2) ES2886123T3 (da)
HK (1) HK1199269A1 (da)
HR (2) HRP20211541T1 (da)
HU (2) HUE042531T2 (da)
IL (2) IL233410A0 (da)
IN (1) IN2014CN04645A (da)
JO (1) JO3547B1 (da)
LT (2) LT3453723T (da)
MX (1) MX358518B (da)
MY (1) MY168748A (da)
NZ (1) NZ626242A (da)
PH (1) PH12014501613B1 (da)
PL (2) PL2809681T3 (da)
PT (2) PT2809681T (da)
RS (2) RS62454B1 (da)
SG (1) SG11201403222UA (da)
SI (2) SI3453723T1 (da)
TW (1) TWI591073B (da)
UY (1) UY34603A (da)
WO (1) WO2013116296A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ626242A (en) 2012-01-31 2017-02-24 Regeneron Pharma Anti-asic1 antibodies and uses thereof
CA2945498A1 (en) * 2014-04-15 2015-10-22 Sorrento Therapeutics, Inc. Antibody therapeutics that bind wisp1
HUE050007T2 (hu) 2014-05-16 2020-11-30 Ablynx Nv Immunglobulin variábilis domének
CN105233286B (zh) * 2015-09-10 2018-10-30 上海交通大学医学院 含酸敏感离子通道调控剂的制剂及其在治疗瘙痒中的用途
CN105713089B (zh) * 2016-02-26 2019-08-06 上海科技大学 一种特异性抑制酸敏感离子通道i型的全人抗体
WO2018085441A1 (en) * 2016-11-01 2018-05-11 Berg Llc Filamin b binding proteins and uses thereof
MD3638698T2 (ro) * 2018-01-26 2021-07-31 Regeneron Pharma Anticorpi anti-TMPRSS2 și fragmente de legare al antigenului
EP3980456A4 (en) * 2019-06-04 2023-01-18 Shanghaitech University AFFINITY MATURED ANTI-ASIC1A ANTIBODIES
MX2022000325A (es) * 2019-07-11 2022-03-25 Memorial Sloan Kettering Cancer Center Anticuerpos dirigidos contra dll3 y usos de los mismos.
GB2600333A (en) * 2019-07-23 2022-04-27 Univ Shanghai Technology ASICI channel antagonist antibody
AU2020346886A1 (en) * 2019-09-13 2022-04-14 Memorial Hospital For Cancer And Allied Diseases Anti-CD371 antibodies and uses thereof
IL310700A (en) * 2021-08-09 2024-04-01 Merck Patent Gmbh Proteins that uncouple cell-mediated tumor cytotoxicity from proinflammatory cytokine release
CN118159558A (zh) * 2021-09-02 2024-06-07 纪念斯隆-凯特琳癌症中心 抗dll3抗体和其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2759373B1 (fr) 1997-02-11 2001-05-04 Centre Nat Rech Scient Nouveau canal cationique neuronal de mammifere sensible a l'acidite, son clonage et ses applications
WO1999021981A1 (en) 1997-10-29 1999-05-06 Mcgill University Dna encoding a human proton-gated ion channel and uses thereof
US6287859B1 (en) 1998-08-05 2001-09-11 Centre National De La Recherche Identification, functional expression and chromosal localization of a sustained human proton-gated cation channel
CA2304494A1 (en) 2000-04-20 2001-10-20 Philippe Seguela A novel heteromultimeric ion channel receptor and uses thereof
US6635432B1 (en) 2000-04-25 2003-10-21 University Of Iowa Research Foundation Peptide potentiation of acid-sensory ion channel in pain
US7132505B1 (en) 2001-05-10 2006-11-07 Centre National De La Recherche Scientifique - Cnrs Polypeptide inhibiting a proton-gated Na+ channel, a nucleic acid coding for such polypeptide and a method of manufacturing an ASIC1a channel blocker
CA2352702A1 (en) * 2001-07-18 2003-01-18 Philippe Seguela Novel human proton gated ion channel
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20070197583A1 (en) 2002-03-29 2007-08-23 Welsh Michael J Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction
US20030186860A1 (en) 2002-03-29 2003-10-02 Welsh Michael J. Novel compositions and methods for modulating the acid-sensing ion channel (ASIC)
AU2003220525A1 (en) * 2002-03-29 2003-10-20 Abgenix, Inc. Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
WO2005025518A2 (en) * 2003-09-11 2005-03-24 The Uab Research Foundation Inhibition of inward sodium currents in cancer
WO2005074923A1 (en) 2004-02-03 2005-08-18 Agt Biosciences Limited Methods and compositions
JP2007530664A (ja) 2004-03-30 2007-11-01 ペインセプター ファーマ コーポレーション ゲートイオンチャンネルを調節するための組成物及び方法
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US7192500B2 (en) 2004-04-30 2007-03-20 Kimberly-Clark Worldwide, Inc. Process for making a garment including an absorbent assembly
US8030442B2 (en) 2004-09-16 2011-10-04 Morehouse School Of Medicine Treatment of injury to the brain by inhibition of acid sensing ion channels
WO2006068953A2 (en) * 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
MX2007013304A (es) * 2005-04-26 2007-12-13 Pfizer Anticuerpos de p-caderina.
MX2008014804A (es) * 2006-06-02 2009-01-27 Regeneron Pharma Anticuerpos de afinidad elevada a receptor de il-6 humano.
EP2975057A1 (en) * 2006-07-10 2016-01-20 Fujita Health University Novel anti-cd73 antibody
EP2043650A2 (en) 2006-07-14 2009-04-08 Medical Research Council Treatment for demyelinating disease
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
US7598039B2 (en) 2007-01-30 2009-10-06 Academia Sinica Treatment of insulin resistance
ATE483985T1 (de) 2007-04-03 2010-10-15 Ilegusavnid Genetics Resource Mit panikstörungen assoziierte amilorid-sensitive natriumkanäle
WO2008134659A2 (en) * 2007-04-27 2008-11-06 Zymogenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
US20110262395A1 (en) * 2008-05-08 2011-10-27 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
US20090291150A1 (en) 2008-05-21 2009-11-26 University Of Iowa Research Foundation Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity
FR2932091B1 (fr) 2008-06-06 2012-12-28 Centre Nat Rech Scient Effets analgesiques de la toxine peptidique apetx2
DK2356270T3 (da) * 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
GB0922434D0 (en) * 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
CN102234316B (zh) * 2010-05-07 2014-01-29 中国人民解放军军事医学科学院毒物药物研究所 具有增强酸感受离子通道1a电流作用的多肽及其用途
US9371383B2 (en) 2012-01-31 2016-06-21 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof
NZ626242A (en) 2012-01-31 2017-02-24 Regeneron Pharma Anti-asic1 antibodies and uses thereof

Also Published As

Publication number Publication date
TW201335182A (zh) 2013-09-01
EP3453723A2 (en) 2019-03-13
MY168748A (en) 2018-11-30
MX358518B (es) 2018-08-24
JP6302844B2 (ja) 2018-03-28
US20180222976A1 (en) 2018-08-09
EP3453723A3 (en) 2019-04-10
IL254416B (en) 2018-03-29
ES2707599T3 (es) 2019-04-04
JP2015508063A (ja) 2015-03-16
CN104093738A (zh) 2014-10-08
US20160002332A1 (en) 2016-01-07
MX2014008541A (es) 2014-10-24
PH12014501613A1 (en) 2014-10-13
IL233410A0 (en) 2014-08-31
PT2809681T (pt) 2019-02-18
CL2014002019A1 (es) 2015-01-16
AU2013215254A1 (en) 2014-07-03
CY1124778T1 (el) 2022-11-25
PH12014501613B1 (en) 2014-10-13
EP2809681A1 (en) 2014-12-10
PL3453723T3 (pl) 2022-01-03
TWI591073B (zh) 2017-07-11
HK1199269A1 (en) 2015-06-26
US20130195878A1 (en) 2013-08-01
SI3453723T1 (sl) 2021-11-30
EP3453723B1 (en) 2021-08-11
AR089852A1 (es) 2014-09-24
EA201491452A1 (ru) 2014-11-28
US10513557B2 (en) 2019-12-24
KR102111941B1 (ko) 2020-05-18
DK3453723T3 (da) 2021-09-13
SI2809681T1 (sl) 2019-04-30
RS58439B1 (sr) 2019-04-30
HUE042531T2 (hu) 2019-07-29
CN104093738B (zh) 2018-05-18
LT2809681T (lt) 2019-02-11
HUE056335T2 (hu) 2022-02-28
EP2809681B1 (en) 2018-12-05
CA2862332A1 (en) 2013-08-08
RS62454B1 (sr) 2021-11-30
ES2886123T3 (es) 2021-12-16
HRP20211541T1 (hr) 2021-12-24
BR112014018651A2 (pt) 2017-07-04
CA2862332C (en) 2021-05-18
PL2809681T3 (pl) 2019-05-31
JO3547B1 (ar) 2020-07-05
NZ626242A (en) 2017-02-24
US9150648B2 (en) 2015-10-06
PT3453723T (pt) 2021-09-07
AU2013215254B2 (en) 2017-08-31
KR20140125363A (ko) 2014-10-28
LT3453723T (lt) 2021-09-10
SG11201403222UA (en) 2014-07-30
UY34603A (es) 2013-07-31
CY1121368T1 (el) 2020-05-29
IN2014CN04645A (da) 2015-09-18
IL254416A0 (en) 2017-11-30
WO2013116296A1 (en) 2013-08-08
HRP20190358T1 (hr) 2019-04-05
CO7020877A2 (es) 2014-08-11
EA028647B1 (ru) 2017-12-29

Similar Documents

Publication Publication Date Title
JP7500812B2 (ja) 中東呼吸器症候群－コロナウイルススパイクタンパク質に対するヒト抗体
DK2809681T3 (da) ANTI-ASIC1-antistoffer og anvendelser deraf
KR101781786B1 (ko) 사람 안지오포이에틴-2에 대한 고 친화성 사람 항체
AU2013280610B2 (en) Anti-EGFR antibodies and uses thereof
DK2475684T3 (da) Humane højaffnititetsantistoffer mod human protease-aktiveret receptor-2
ES2694153T3 (es) Anticuerpos anti-ErbB3 y usos de los mismos
KR20210129253A (ko) 항-액티빈 a 항체 및 그의 용도
KR20140014067A (ko) 항-cd48 항체 및 그의 용도
KR102563568B1 (ko) 렙틴 수용체에 길항하는 항원-결합 단백질
US20180208656A1 (en) Anti-Prokineticin Receptor (PROKR) Antibodies and Uses Thereof
US9371383B2 (en) Anti-ASIC1 antibodies and uses thereof